Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol.

MLA

Lehnert, Thomas, et al. “Immunotherapy for People with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis: Treatment Response by Demographic, Clinical, and Biomarker Subgroups (PROMISE)-a Systematic Review Protocol.” Systematic Reviews, vol. 11, no. 1, July 2022, p. 134. EBSCOhost, https://doi.org/10.1186/s13643-022-01997-2.

APA

Lehnert, T., Röver, C., Köpke, S., Rio, J., Chard, D., Fittipaldo, A. V., Friede, T., Heesen, C., & Rahn, A. C. (2022). Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol. Systematic Reviews, 11(1), 134. https://doi.org/10.1186/s13643-022-01997-2

Chicago

Lehnert, Thomas, Christian Röver, Sascha Köpke, Jordi Rio, Declan Chard, Andrea V Fittipaldo, Tim Friede, Christoph Heesen, and Anne C Rahn. 2022. “Immunotherapy for People with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis: Treatment Response by Demographic, Clinical, and Biomarker Subgroups (PROMISE)-a Systematic Review Protocol.” Systematic Reviews 11 (1): 134. doi:10.1186/s13643-022-01997-2.